Jennifer W. Carlisle
Distinguished in EGFR Positive Lung Cancer

Dr. Jennifer W. Carlisle

Oncology
Emory health
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
Offers Telehealth
15 Years of Experience
Distinguished in EGFR Positive Lung Cancer
Emory health
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jennifer Carlisle is an Oncologist in Atlanta, Georgia. Dr. Carlisle has been practicing medicine for over 15 years and is rated as a Distinguished provider by MediFind in the treatment of EGFR Positive Lung Cancer. Her top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and EGFR Positive Lung Cancer.

Her clinical research consists of co-authoring 41 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of EGFR Positive Lung Cancer.

Graduate Institution
University Of Florida, 2011.0
Residency
Washington University School of Medicine
Specialties
Oncology
Licenses
Internal Medicine in GA
Board Certifications
American Board Of Internal Medicine, 2019
Fellowships
Emory University School of Medicine
Hospital Affiliations
Emory University Hospital Midtown
Emory University Hospital
Saint Joseph's Hospital Of Atlanta, Inc
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, Atlanta, GA 30322
Call: 404-778-1900

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Cobimetinib
Study Phase: Phase 2
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Drug
Study Drugs: Alectinib, Brigatinib, Carboplatin, Ceritinib, Cisplatin, Crizotinib, Ensartinib, Lorlatinib, Pemetrexed
Study Phase: Phase 2
A Phase 1a/1b Study of Aurora Kinase A Inhibitor VIC-1911 Monotherapy and in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
A Phase 1a/1b Study of Aurora Kinase A Inhibitor VIC-1911 Monotherapy and in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: May 01, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b Neoadjuvant Trial of Sirolimus Followed by Durvalumab (MEDI4736) in Resectable Non-small Cell Lung Cancer
A Phase 1b Neoadjuvant Trial of Sirolimus Followed by Durvalumab (MEDI4736) in Resectable Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: August 22, 2024
Intervention Type: Drug
Study Drugs: Durvalumab, Sirolimus
Study Phase: Phase 1
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: February 23, 2024
Intervention Type: Drug
Study Drugs: Letetresgene autoleucel, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug
Study Drugs: VS-6766, VS-6766+Defactinib
Study Phase: Phase 2
A Multi-Center, Phase Ib/II Study of Combination Treatment of APG-1252 With Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
A Multi-Center, Phase Ib/II Study of Combination Treatment of APG-1252 With Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: July 12, 2022
Intervention Type: Drug
Study Drugs: APG-1252, Paclitaxel
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

41 Total Publications

A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS.
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 17, 2025
View All 41 Publications
Similar Doctors
Suresh S. Ramalingam
Elite in EGFR Positive Lung Cancer
Dr. Suresh S. Ramalingam
Oncology
Elite in EGFR Positive Lung Cancer
Dr. Suresh S. Ramalingam
Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (0.1 miles away)
404-778-1900
Experience:
34+ years
Languages Spoken:
English, Tamil
See accepted insurances
Offers Telehealth

Suresh Ramalingam is an Oncologist in Atlanta, Georgia. Dr. Ramalingam has been practicing medicine for over 34 years and is rated as an Elite provider by MediFind in the treatment of EGFR Positive Lung Cancer. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy.

Conor E. Steuer
Distinguished in EGFR Positive Lung Cancer
Dr. Conor E. Steuer
Oncology
Distinguished in EGFR Positive Lung Cancer
Dr. Conor E. Steuer
Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (0.1 miles away)
404-778-1900
Experience:
17+ years
Languages Spoken:
English
See accepted insurances

Conor Steuer is an Oncologist in Atlanta, Georgia. Dr. Steuer has been practicing medicine for over 17 years and is rated as an Elite provider by MediFind in the treatment of EGFR Positive Lung Cancer. His top areas of expertise are Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Tissue Biopsy, and Gastrostomy.

Distinguished in EGFR Positive Lung Cancer
Dr. Ticiana Leal
Oncology
Distinguished in EGFR Positive Lung Cancer
Dr. Ticiana Leal
Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (0.1 miles away)
404-778-1900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ticiana Leal is an Oncologist in Atlanta, Georgia. Dr. Leal is rated as an Elite provider by MediFind in the treatment of EGFR Positive Lung Cancer. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma.

VIEW MORE EGFR POSITIVE LUNG CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Carlisle's expertise for a condition
ConditionClose
    • Distinguished
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Carlisle is
      Distinguished
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • EGFR Positive Lung Cancer
      Dr. Carlisle is
      Distinguished
      . Learn about EGFR Positive Lung Cancer.
      See more EGFR Positive Lung Cancer experts
    • Lung Cancer
      Dr. Carlisle is
      Distinguished
      . Learn about Lung Cancer.
      See more Lung Cancer experts
    • Non-Small Cell Lung Cancer (NSCLC)
      Dr. Carlisle is
      Distinguished
      . Learn about Non-Small Cell Lung Cancer (NSCLC).
      See more Non-Small Cell Lung Cancer (NSCLC) experts
    • Pleuropulmonary Blastoma
      Dr. Carlisle is
      Distinguished
      . Learn about Pleuropulmonary Blastoma.
      See more Pleuropulmonary Blastoma experts
    • Small Cell Lung Cancer (SCLC)
      Dr. Carlisle is
      Distinguished
      . Learn about Small Cell Lung Cancer (SCLC).
      See more Small Cell Lung Cancer (SCLC) experts
    View All 7 Distinguished Conditions
    • Advanced
    • Large-Cell Lung Carcinoma
      Dr. Carlisle is
      Advanced
      . Learn about Large-Cell Lung Carcinoma.
      See more Large-Cell Lung Carcinoma experts
    • Lung Adenocarcinoma
      Dr. Carlisle is
      Advanced
      . Learn about Lung Adenocarcinoma.
      See more Lung Adenocarcinoma experts
    • Mesothelioma
      Dr. Carlisle is
      Advanced
      . Learn about Mesothelioma.
      See more Mesothelioma experts
    • Experienced
    • Melanoma
      Dr. Carlisle is
      Experienced
      . Learn about Melanoma.
      See more Melanoma experts
    • Metastatic Brain Tumor
      Dr. Carlisle is
      Experienced
      . Learn about Metastatic Brain Tumor.
      See more Metastatic Brain Tumor experts
    • Metastatic Pleural Tumor
      Dr. Carlisle is
      Experienced
      . Learn about Metastatic Pleural Tumor.
      See more Metastatic Pleural Tumor experts
    • Neuroendocrine Tumor
      Dr. Carlisle is
      Experienced
      . Learn about Neuroendocrine Tumor.
      See more Neuroendocrine Tumor experts
    • Posterior Fossa Tumor
      Dr. Carlisle is
      Experienced
      . Learn about Posterior Fossa Tumor.
      See more Posterior Fossa Tumor experts
    • Primitive Neuroectodermal Tumor (PNET)
      Dr. Carlisle is
      Experienced
      . Learn about Primitive Neuroectodermal Tumor (PNET).
      See more Primitive Neuroectodermal Tumor (PNET) experts
    View All 7 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.